Protein P (hepatitis B virus)

Protein P
other names	HBV Pol
Mass / length primary structure	845 amino acids , 94,768 Da
Identifier
External IDs	UniProt : P17100 ;
Enzyme classification
EC, category	2.7.7.7
	Orthologue ( hepatitis B virus )
Entrez	944565
UniProt	P17100 ;
PubMed search	944565

Protein P is a protein from the group of reverse transcriptases and is produced by the hepatitis B virus .

properties

Protein P is bound to viral RNA in the cytosol within the capsid of HBV from HBcAg . The RNA is then transcribed into DNA by protein P. As a reverse transcriptase, Protein P is an RNA- or DNA-dependent DNA polymerase . Protein P also has a 3 ': 5' endonuclease activity . For reverse transcription, protein P binds to the epsilon loop of pregenomic RNA, protein P itself serves as a primer and is therefore covalently linked to the 5 'end of the (-) DNA. The (+) DNA is then generated using the (-) DNA template. After budding and a renewed infection of a cell, the double-stranded DNA with the capsid is imported into the cell nucleus , where the double-stranded DNA is closed to form cccDNA and the protein P is separated from the genome.

Deoxynucleoside triphosphate + DNA (n) ↔ diphosphate + DNA (n + 1).

Applications

Lamivudine , penciclovir , tenofovir , adefovir and entecavir inhibit protein P of non-resistant HBV. Protein P is also being investigated for the treatment of HBV infections.

Web links

MeSH Protein P (hepatitis B virus)

Individual evidence

↑ ^a ^b ^c ^d ^e ^f ^g Uniprot : P - Protein P - Hepatitis B virus genotype A2 subtype adw2 (isolate Germany / 991/1990) (HBV-A) - P gene & protein. In: uniprot.org. June 20, 2018, accessed February 26, 2018 .
↑ SK Ono-Nita, N. Kato, Y. Shiratori, T. Masaki, KH Lan, FJ Carrilho, M. Omata: YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full- length viral DNA transfection. In: Hepatology (Baltimore, Md.). Volume 29, Number 3, March 1999, pp. 939-945. ISSN 0270-9139 , doi: 10.1002 / hep.510290340 . PMID 10051501 .
↑ T. Shaw, SS Mok, SA Locarnini: Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir. In: Hepatology (Baltimore, Md.). Volume 24, Number 5, November 1996, pp. 996-1002. ISSN 0270-9139 , doi: 10.1002 / hep.510240504 , PMID 8903366 .
↑ LJ Scott, HL Chan: Tenofovir Alafenamide: A Review in Chronic Hepatitis B. In: Drugs. Volume 77, Number 9, June 2017, pp. 1017-1028, doi : 10.1007 / s40265-017-0754-9 , PMID 28493172 .
^ Y. Pei, C. Wang, SF Yan, G. Liu: Past, Current, and Future Developments of Therapeutic Agents for Treatment of Chronic Hepatitis B Virus Infection. In: Journal of medicinal chemistry. Volume 60, number 15, August 2017, pp. 6461-6479, doi : 10.1021 / acs.jmedchem.6b01442 , PMID 28383274 .

[uniprot-17100-1] ↑ ^a ^b ^c ^d ^e ^f ^g Uniprot : P - Protein P - Hepatitis B virus genotype A2 subtype adw2 (isolate Germany / 991/1990) (HBV-A) - P gene & protein. In: uniprot.org. June 20, 2018, accessed February 26, 2018 .

[pmid10051501-2] SK Ono-Nita, N. Kato, Y. Shiratori, T. Masaki, KH Lan, FJ Carrilho, M. Omata: YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full- length viral DNA transfection. In: Hepatology (Baltimore, Md.). Volume 29, Number 3, March 1999, pp. 939-945. ISSN 0270-9139 , doi: 10.1002 / hep.510290340 . PMID 10051501 .

[pmid8903366-3] T. Shaw, SS Mok, SA Locarnini: Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir. In: Hepatology (Baltimore, Md.). Volume 24, Number 5, November 1996, pp. 996-1002. ISSN 0270-9139 , doi: 10.1002 / hep.510240504 , PMID 8903366 .

[4] LJ Scott, HL Chan: Tenofovir Alafenamide: A Review in Chronic Hepatitis B. In: Drugs. Volume 77, Number 9, June 2017, pp. 1017-1028, doi : 10.1007 / s40265-017-0754-9 , PMID 28493172 .

[5] Y. Pei, C. Wang, SF Yan, G. Liu: Past, Current, and Future Developments of Therapeutic Agents for Treatment of Chronic Hepatitis B Virus Infection. In: Journal of medicinal chemistry. Volume 60, number 15, August 2017, pp. 6461-6479, doi : 10.1021 / acs.jmedchem.6b01442 , PMID 28383274 .